BLOOD CANCER BREAKTHROUGHS PRESENTED AT ASCO
Leading The Way Toward A New Approach To Treating Many Forms Of Cancer
Two breakthroughs in the treatment of blood cancer were presented at the American Society of Clinical Oncology (ASCO) meeting in Atlanta. Doctors presented new data that illustrates the dramatic progress being made in the treatment of multiple myeloma, a cancer in the bone marrow that affects production of red cells, white cells and stem cells, in extending survival and increasing quality of life.
Blood cancers are the second leading cause of death among all cancers, and as the population ages, blood cancers are the fastest growing among all cancers.
An advancement in multiple myeloma was found with the drug Thalomid®. When used in the treatment of newly diagnosed elderly patients with the disease, it was found to be more effective than stem cell transplants. Thalomid is the newest generation of the infamous drug thalidomide, which received national attention in the late 1950s for causing birth defects. This once dangerous drug is now bringing new hope to a new generation of patients.
In another finding, during clinical trials, Revlimid® was shown to extend life for patients taking the drug. This is a major advancement as the majority of multiple myeloma can now consider multiple myeloma a chronic, manageable condition.
Revlimid, the second generation of Thalomid, works in a similar way to the original drug, but has fewer side effects and can be used on patients who have relapsed or whom other therapies are not working.
- Hardy Jones, Multiple Myeloma Patient
- Paul Nicholss, Multiple Myeloma Patient
- Brian Durie, M.D., International Multiple Myeloma Foundation
- Production Shot of Revlimid and Thalomid
- Patient Lifestyle
- Product Shots
VIDEO PROVIDED BY: "International Multiple Myeloma Found"
FOR TECHNICAL INFORMATION OR HARD COPY REQUESTS CALL:
MultiVu Media Relations: 1-800-653-5313 x. 3